A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
This is a Phase I open-label study to evaluate the pharmacokinetic (PK) profile of a single oral dose of vadadustat in subjects with hepatic impairment(HI) compared to healthy matched control subjects with normal hepatic function.
Key facts
- Study ID
- NCT03799848
- Run by
- Akebia Therapeutics
- People needed
- 24
- Starts
- 2018-06-12
- Expected to finish
- 2018-10-18
- Last updated by the study team
- 2019-03-22
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- Prism Clinical Research — Saint Paul, Minnesota, United States
- American Research Corporation at the University of Texas Liver Institute — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.